US Patent

US12290503 — Compositions and methods for treating epilepsy, seizures and other conditions

Method of Use · Assigned to Tulex Pharmaceuticals Inc · Expires 2040-08-21 · 14y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects compositions and methods for the liquid oral administration of topiramate and its salts for treating various conditions.

USPTO Abstract

Compositions are provided for the liquid oral administration of topiramate and its salts. The invention further provides methods for treating diseases and disorders using the compositions.

Drugs covered by this patent

Topamax (topiramate) · Janssen

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3413`	—	Topamax

Patent Metadata

Patent number: US12290503
Jurisdiction: US
Classification: Method of Use
Expires: 2040-08-21
Drug substance claim: No
Drug product claim: Yes
Assignee: Tulex Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.